COVID-19 in chronic myeloid leukemia patients in Latin America

Pagnano, Kátia Bórgia Barbosa; Peralta, Evelyn Herrera; Navarro, Juan Ramón; Salas, Lourdes Del Rosario David; Delgado, Nora Sexto; Moiraghi, Beatriz; Toreli, Ana Carolina Mourão; Perobelli, Leila Martins; Fechio, Leonardo; Quixadá, Acy Telles de Souza; Funke, VAM; Bendit, Israel; Seguro, Fernanda Salles; Pilleux, Lilian; Bortolini, Jaisson; Lourenço, André; Sapelli, Jaqueline; Nucci, Fabio Moore; Pavlovsky, Carolina; Oliveira, Luciene; Moura, Muriel Silva; Palma, Leonardo Carvalho; Gonçalves, Natália N; Conchon, Mônika; Hokama, Paula de Oliveira Montandon; Almeida, L. L. de; Zulli, Roberto; Souza, Cármino Antonio De; Boquimpani, Carla

doi:10.1080/10428194.2021.1950709

Cited by 7 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also addressing similar issues with this study, reporting that 24% of CML-centers altered their molecular monitoring schedule with more than half suspending the strategy for treatment free remission, citing difficulties in frequent monitoring ( 4 ). Other studies presented a slightly more pessimistic outlook with 11-13% mortality rates for COVID-19 in CML-CP patients in the first year of the pandemic ( 6 , 7 ). Differences of age, screening practices, applied preventive methods for avoiding COVID-19 transmission, ethnicity, and comorbidities may be among the variables responsible from the discordance of mortality rates between studies.…”

Section: Discussionmentioning

confidence: 98%

“…The elective clinical procedures and appointments were also mostly delayed in the first year of the pandemic due to the uncertainty of transmission rates, at-risk populations, and the unavailability of the vaccine. Whether CML-CP patients were under a higher risk for severe COVID-19 due to the disease itself or its treatment were addressed in a few studies earlier during the pandemic (3)(4)(5)(6)(7). The advanced age of most CML-CP patients, pulmonary AEs of dasatinib, drugdrug interactions between TKIs and COVID-19 treatments, thrombogenicity of ponatinib and nilotinib were especially concerning at the onset of the pandemic.…”

Section: Discussionmentioning

confidence: 99%

“…Whether CML-CP patients were under a higher risk for severe COVID-19 due to the disease itself or its treatment were addressed in a few studies earlier during the pandemic ( 3 – 7 ). The advanced age of most CML-CP patients, pulmonary AEs of dasatinib, drug-drug interactions between TKIs and COVID-19 treatments, thrombogenicity of ponatinib and nilotinib were especially concerning at the onset of the pandemic.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase

Yılmaz

Küçükyurt²,

Tunç³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

IntroductionCOVID-19 immediately became a major consideration in the management of chronic myeloid leukemia (CML). The influence of such considerations on viral transmission rates and leukemic control remain to be explored. We conducted this study to identify these alterations and to investigate their clinical consequences.MethodsThis was a cross-sectional study, performed at a single institution on CML patients who were interviewed with a survey. We compared variables concerning new attitudes in the pandemic era between the 12-month periods before and after the pandemic onset. Outcome data were attained from the hospital archives.FindingsThe number of patients receiving regular outpatient care for CML in chronic phase was 210, 91% had achieved at least major molecular responses. We assessed survival, progression, number of clinical visits of all, performed the survey on 89% and evaluated molecular responses on 86.6% of these patients. The frequency of clinical and molecular monitoring was significantly reduced during the pandemic deviating significantly from the guidelines. Frequency of death, progression, loss of molecular response was not significantly increased during the pandemic era despite a few cases where the delay in assessment possibly played a role in the unfavorable outcomes. There were no COVID related deaths or disabilities.ConclusionThe case-based untoward events would have probably been better managed with a more efficient communication web between patients, hematologists, and the laboratory. Therefore, it seems reasonable to consider whether such communicative paths are functional before giving up on the set schedule of CML management at times of uncertainty.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase

Yılmaz

Küçükyurt²,

Tunç³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Лечение злокачественных заболеваний системы крови у пациентов с COVID-19 у 92 пациентов с ХМЛ, констатировали тяжелое тече ние только в 26 %, а летальность -в 11,9 % случаев. Исследователи выделили факторы благоприятного прогноза: полный молекулярный ответ, прием ИТК, ремиссия ХМЛ без терапии [13]. Интересным пред ставляется, что число госпитализированных больных ХМЛ, инфицированных SARSCoV2, в нашем реги стре было в 2,2 раза больше, чем в исследовании M. Breccia и соавт.…”

Section: характеристика пациентов 1-й и 2-й групп на момент исследова...unclassified

“…В некоторых исследованиях показано, что онкогематологические больные более подвержены заражению SARSCoV2, чем здоровые лица и пациенты со ЗНО, и имеют худший прогноз вследствие нарушения в иммунной системе, обуслов ленного как самим заболеванием, так и проводимой иммуносупрессивной терапией [7][8][9][10]. Обобщенных данных о течении инфекции COVID19 у пациентов с ХМЛ опубликовано немного [11][12][13]. W. Li и соавт.…”

Section: Introductionunclassified

COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic

et al. 2022

View full text Add to dashboard Cite

Background. Oncohematological patients are more predispose to SARS-CoV-2 infection than healthy individuals and patients with malignant neoplasms, and also they have a worse prognosis, which is because of immune system disorders, both due to the underlying disease and as a result of immunosuppressive therapy. There is limited data regarding the impact of SARS-CoV-2 infection on the survival of patients with chronic myeloid leukemia (CML).Aim. To evaluate the course and outcome of COVID-19 in patients with CML in the Orenburg region during the SARS-CoV-2 pandemic.Materials and methods. All 166 patients with CML over 18 years of age were analyzed during the COVID-19 pandemic between february 2020 and December 2021. The source of information was data from the personalized register of patients with CML and the unified state health information system.Results. The proportion of SARS-CoV-2 infection among patients with CML was 36 %. The risk of infection was not affected by age, gender, work features, place of residence, phase or duration of the disease, and therapy. underwent COVID-19 patients were 1.6 times more likely to be overweight and 2 times more likely to have a second cancer. A significant increase in the number of outpatient visits to polyclinics and number of hospital admissions during the pandemic was revealed in the group of patients who had SARS-CoV-2 infection. underwent COVID-19 patients were over 60 years of age in 48.3 % of cases and had one or more comorbidities in 77.6 % cases. SARS-CoV-2-infected patients with CML had a favorable outcome: a mild course of infection in 75.9 % of cases and a low mortality rate - 6.8 % (4 of 58 patients) were observed. COVID-19 was recognized as the cause of death in only 2 patients with optimal molecular response and comorbidity. In two other patients who underwent COVID-19, the progression of CML to a blast crisis was recognized as the cause of death. There were no significant differences in mortality level in the group of patients who had SARS-CoV-2 infection and those who did not have COVID-19.Conclusion. patients with CML living in the Orenburg region have a low susceptibility to SARS-CoV-2 infection and a mild course of the disease. The mortality rate for CML patients infected with SARS-CoV-2 was 6.8 %. unfavorable factors in the overall survival of patients with CML infected with SARS-CoV-2 were high comorbidity and blast crisis. Reducing the number of outpatient visits during the pandemic and using remote medical consultations is likely to reduce the risk of SARS-CoV-2 infection.

show abstract

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States

Toreli,

Miranda-Galvis,

Sharara

et al. 2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

COVID-19 in chronic myeloid leukemia patients in Latin America

Cited by 7 publications

References 29 publications

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase

COVID-19 infection in patients with chronic myeloid leukemia in the Orenburg region during the SARS-CoV-2 pandemic

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States

Contact Info

Product

Resources

About